November 08, 2024
Hello team, Please find our social listening snapshot below for 10/26 - 11/08, along with a dashboard snapshot PDF attached.
LEO Pharma
Top LEO Pharma Company & Drug Discussions
- Company Mentions:
- SVP of Pharmaceutical Production and Supply Chain at Lundbeck, Kristian Sibilitz, joins LEO Pharma as EVP. (MedWatch)
- tralokinumab (ADBRY):
- Coverage from Pharmaceutical Technology, PMLive, Dermatology Times, Dermatology Advisor, and Healio highlights the long-term ECZTEND trial results presented at the 2024 Fall Clinical, showcasing ADBRY’s sustained efficacy with consistently low EASI, DLQI, and pruritus NRS scores among patients.
- A patient who tried VTAMA without success asks about others’ experiences with ADBRY on Reddit, where another user highlights the ease of ADBRY’s autoinjector and mentions the copay assistance program. In a separate thread, patients discuss side effects, such as skin peeling, dryness, and occasional limb weakness.
- Dr. Eingun James Song, MD, FAAD, shared a recap of his four clinical insights from the Fall Clinical, noting that acantholytic disorders like Hailey-Hailey disease, Grover’s disease, and Darier disease may benefit from biologic therapies such as ADBRY. (LinkedIn, Dermatology Times).
- delgocitinib (Anzupgo):
- Post-trial exit interviews of the phase 3 DELTA 1 clinical trial for delgocitinib finds that CHE negatively impacts the quality of life for most patients. (Dermatology Times)
- BioSpace syndicates a press release highlighting delgocitinib data at the Fall Clinical.
Other top Atopic Dermatitis (AD) & Chronic Hand Eczema (CHE) Discussions
- The 2024 Fall Clinical generates over 90 mentions and 400 social post engagements, with competitive conversations centered on OPZELURA, EBGLYSS, RINVOQ, DUPIXENT, and VTAMA. Highlights:
- James Del Rosso’s presentation discussing the MOA and benefits of topicals like OPZELURA is summarized in Dermatology Times.
- HCP Live, The Pharma Data, Dermatology Times, The Pharma Letter, andWorld Pharmaceuticals cover results from phase 3b of the ADapt study, highlighting that 57% of patients achieved EASI-75 at 16 weeks with EBGLYSS—after previously being treated with DUPIXENT.
- Michael Cameron, MD FAAD, shares his key takeaways from the Fall Clinical, mentioning that RINVOQ’s additional indications (Vitiligo and Alopecia Areata) is contributing to “The Year of the JAK”.
- HCP Live interviews Level Up trial investigator, Christopher Bunick, MD, PhD, about its recent findings regarding RINVOQ for AD.
- PMLive, Contemporary Pediatrics, Healio, and the Dermatology Digest cover results from the ADORING 3 trial of tapinarof presented at the Fall Clinical, highlighting that 51.9% of patients entered with or achieved complete disease clearance at least once during the 48-week study.
- Other discussions:
- Dermatology Times publishes key findings from a study on Dupilumab, showing substantial efficacy after prolonged treatment.
- A phase 3 trial of stapokibart in China for AD shows long-term efficacy and safety, improving symptoms after over 52 weeks. (HCPLive)
- The FDA pushes the PDUFA date of tapinarof cream for AD to 2025. (Contemporary Pediatrics)
- Karan Lal DO, MS FAAD, is interviewed in an article about Topical Steroid Withdrawal in HealthCentral, where he recommends the use of OPZELURA.
- A study links severe AD to an increased risk of glaucoma surgery. (Medical Dialogues)
Dr. Reddy’s Laboratories
- Company Mentions:
- Dr. Reddy’s recalls more than 300k bottles of cinacalcet, a thyroid drug, due to the presence of a known carcinogen. (Fierce Pharma)
- Erez Israeli, CEO of Dr Reddy’s, is interviewed on CNBC to discuss the moves he is undertaking to position the company as a market leader in India.
- denosumab:
- The FDA accepts Organon and Shanghai Henlius Biotech’s BLA for HLX14, a Denosumab Biosimilar. (HCPLive, Press Release)
- COYA 302:
- Coya Therapeutics reports a positive immune response, safety, in a mid-stage Alzheimer’s drug trial of COYA 301. (Reuters)
- Coya Therapeutics announces Arun Swaminathan, Ph.D., as its new CEO. (Press Release)
- Howard Berman, Ph.D, executive chairman at Coya Therapeutics, is interviewed by Bioprocess Online to discuss the company’s development of a combination biologic.
Paratek Pharmaceuticals
- omadacycline (NUZYRA):
- Paratek announces top-line results from its 12-week phase 2b study of omadacycline in adult patients with NTM—showing favorable improvement in frequency and severity of the most common symptoms. (Press Release)